Synuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study

Synuclein‐γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG‐8023).

[1]  D. Levine,et al.  The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  B. Karlan,et al.  Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations , 2015, Modern Pathology.

[3]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[4]  Y. Shao,et al.  Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption , 2014, Molecular oncology.

[5]  C. Shou,et al.  Unconventional secretion of synuclein‐γ promotes tumor cell invasion , 2014, The FEBS journal.

[6]  Weicai Chen,et al.  siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK , 2014, Journal of breast cancer.

[7]  M. Tambas,et al.  Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients , 2014, Tumor Biology.

[8]  W. Liang,et al.  Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption , 2014, Oncogene.

[9]  M. Stoler,et al.  HER2 Immunohistochemistry Significantly Overestimates HER2 Amplification in Uterine Papillary Serous Carcinomas , 2014, The American journal of surgical pathology.

[10]  T. Hachisuga,et al.  Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade , 2014, The journal of obstetrics and gynaecology research.

[11]  Mingjie Zhu,et al.  Synuclein γ Compromises Spindle Assembly Checkpoint and Renders Resistance to Antimicrotubule Drugs , 2014, Molecular Cancer Therapeutics.

[12]  Mingjie Zhu,et al.  Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer , 2013, Medical Oncology.

[13]  Richard G. Moore,et al.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. , 2013, Gynecologic oncology.

[14]  G. Chong,et al.  The correlation between expression of synuclein-gamma, glucose transporter-1, and survival outcomes in endometrioid endometrial carcinoma. , 2013, European journal of gynaecological oncology.

[15]  Yongwei Yu,et al.  Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression , 2012, BMC Cancer.

[16]  L. Massuger,et al.  Pure Compared With Mixed Serous Endometrial Carcinoma: Two Different Entities? , 2012, Obstetrics and gynecology.

[17]  T. Kasamatsu,et al.  Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma , 2012, Cancer science.

[18]  C. Shou,et al.  Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas. , 2012, Hepato-gastroenterology.

[19]  Song Liu,et al.  Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. , 2012, Gynecologic Oncology.

[20]  Gong Yang,et al.  The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer , 2011, Clinical Cancer Research.

[21]  D. Giannarelli,et al.  Uterine Papillary Serous, Clear Cell, and Poorly Differentiated Endometrioid Carcinomas: A Comparative Study , 2011, International Journal of Gynecologic Cancer.

[22]  L. Potters,et al.  Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha. , 2010, The American journal of pathology.

[23]  C. Sung,et al.  Minor Serous and Clear Cell Components Adversely Affect Prognosis in ‘‘Mixed-Type’’ Endometrial Carcinomas: A Clinicopathologic Study of 36 Stage-I Cases , 2010, Reproductive Sciences.

[24]  C. Shou,et al.  Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen , 2010, BMC Cancer.

[25]  J. Kim,et al.  Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. , 2009, Gynecologic oncology.

[26]  A. Mariani,et al.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer , 2008, British Journal of Cancer.

[27]  C. Shou,et al.  Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients. , 2008, Cancer letters.

[28]  M. Davy,et al.  Serous carcinoma of the uterus—determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation , 2007, International Journal of Gynecologic Cancer.

[29]  V. Uversky,et al.  Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. , 2007, Cancer research.

[30]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[31]  M. Fraser,et al.  Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. , 2006, Cancer research.

[32]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[33]  Jingwen Liu,et al.  Synuclein Gamma Inhibits the Mitotic Checkpoint Function and Promotes Chromosomal Instability of Breast Cancer Cells , 2005, Breast Cancer Research and Treatment.

[34]  E. Siegel,et al.  Amplification of c‐erbB2 oncogene , 2005, Cancer.

[35]  E. Siegel,et al.  Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. , 2005, American journal of obstetrics and gynecology.

[36]  T. Isono,et al.  Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ‐synuclein, and catechol‐o‐methyltransferase) identified by proteomic analysis , 2004, Cancer science.

[37]  E. Asselin,et al.  AKT involvement in cisplatin chemoresistance of human uterine cancer cells. , 2004, Gynecologic oncology.

[38]  K. Hess,et al.  Overexpression of synuclein‐γ in pancreatic adenocarcinoma , 2004 .

[39]  I. Goldberg,et al.  γ Synuclein, a Novel Heat-Shock Protein-Associated Chaperone, Stimulates Ligand-Dependent Estrogen Receptor α Signaling and Mammary Tumorigenesis , 2004, Cancer Research.

[40]  I. Goldberg,et al.  Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. , 2004, Cancer research.

[41]  K. Lu,et al.  Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD". , 2004, Gynecologic oncology.

[42]  Jingwen Liu,et al.  Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1 , 2003, Oncogene.

[43]  Yangfu Jiang,et al.  Stage-specific Expression of Breast Cancer-specific Gene γ-Synuclein , 2003 .

[44]  I. Goldberg,et al.  Stimulation of Estrogen Receptor Signaling by γ Synuclein , 2003 .

[45]  G. Mills,et al.  Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells* , 2003, Journal of Biological Chemistry.

[46]  Yangfu Jiang,et al.  Stage-specific expression of breast cancer-specific gene gamma-synuclein. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  I. Goldberg,et al.  Stimulation of estrogen receptor signaling by gamma synuclein. , 2003, Cancer research.

[48]  A. Godwin,et al.  γ-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways* , 2002, The Journal of Biological Chemistry.

[49]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[50]  D. Schoenfeld.  The asymptotic properties of nonparametric tests for comparing survival distributions , 1981 .